SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline expansion
The company leverages data-driven strategies to commercialize improved therapies, launching two products in 2026 and building a robust pipeline targeting large markets. Revenue is growing steadily, supported by strong commercial infrastructure and ongoing expansion efforts.Based on Scienture Holdin…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.